Today - Friday, December 13, 2013
7:04 AMAstraZeneca gout drug hits Phase III goal, but safety an issue
- AstraZeneca's (AZN +2.3%) Lesinurad treatment for gout met the primary goal of a Phase III study, although it caused a number of side effects, some of which were serious.
- The study tested Lesinurad for use in the small number of patients who are unable to take rival therapies allopurinol and febuxostat.
- The side effects included increased levels of serum creatinine, which are an important indicator of renal health.
- AstraZeneca is now waiting for the outcomes of three other Phase III trials, which are testing Lesinurad in combination with other drugs. (PR)